<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mpath ids='MPATH_177'>Angiogenesis</z:mpath> is the process of formation of new blood vessels due to over expression of VEGF (vascular endothelial growth factor) which plays a critical role in the growth and development of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> types </plain></SENT>
<SENT sid="1" pm="."><plain>With the advancement in understanding of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> and VEGF, there have been a number of agents developed to target VEGF for the treatment of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>These targeted agents can affect downstream VEGF signal transduction by unique mechanisms at different cellular and extracellular levels </plain></SENT>
<SENT sid="3" pm="."><plain>FDA has recently approved Aflibercept or VEGF-Trap in August 2012 for the treatment of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>It is a recombinant, decoy receptor fusion protein, rationally designed to block <z:mpath ids='MPATH_177'>angiogenesis</z:mpath> by targeting VEGF-A, VEGF-B and placental growth factor </plain></SENT>
<SENT sid="5" pm="."><plain>VEGF-Trap exerts its antiangiogenic effects through regression of <z:e sem="disease" ids="C1658953" disease_type="Neoplastic Process" abbrv="">tumor vasculature</z:e>, remodelling or normalization of surviving vasculature and inhibition of new <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> vessel growth </plain></SENT>
<SENT sid="6" pm="."><plain>In this review, pre-clinical and clinical data have been summarized for aflibercept alone and in combination with chemotherapy to explore its efficacy and benefits in <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e>, <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, <z:e sem="disease" ids="C0007131" disease_type="Neoplastic Process" abbrv="NSCLC">non-small cell lung cancer</z:e>, <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo>, <z:hpo ids='HP_0100843'>glioblastoma</z:hpo>, <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and <z:e sem="disease" ids="C0007134" disease_type="Neoplastic Process" abbrv="">renal cell cancer</z:e> <z:e sem="disease" ids="C1520166" disease_type="Experimental Model of Disease" abbrv="">xenograft models</z:e> </plain></SENT>
</text></document>